The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription

Biochemical and Biophysical Research Communications

Volumn 307, Issue 1, 2003, Pages 23-30

  Strobach, Dorothea ^a   Lorenz, Reinhard L ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

ABCA1; Atherosclerosis; Bisphosphonates; CD36; Cholesterol; GGPP; Ibandronate; Macrophage

Indexed keywords

ABC TRANSPORTER A1; BISPHOSPHONATE IBANDRONATE; BISPHOSPHONIC ACID DERIVATIVE; CD36 ANTIGEN; CHOLESTEROL; GERANYLGERANIOL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CHOLESTEROL TRANSPORT; DOWN REGULATION; DRUG EFFECT; FOAM CELL; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HUMAN CELL; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 0037711842     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01127-6     Document Type: Article

References (58)

1. Russell R.G.G., Croucher P.I., Rogers M.J. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos. Int. Suppl. 2:1999;S66-S80.
2. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckmann S.P., Mönkkönen J., Frith J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88:2000;2961-2978.
3. Francis M.D., Russell R.G.G., Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 165:1969;1264-1266.
4. Bassett C.A., Donath A., Macagno F., Preisig R., Fleisch H., Francio M.D. Diphosphoantes in the treatment of myositis ossificans. Lancet. 2:1969;845.
5. Fleisch H., Russell R.G.G., Bisaz S., Mühlbauer R.C., Williams D.A. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. J. Clin. Invest. 1:1970;12-18.
6. Lantto T., Järvi K., Toivio I., Vahatalo S., Vorne M. The visualization of femoral vessels in delayed bone scans, a sign of atherosclerosis? A comparison of 99mTc-MDP and ppmTc-DPD. Eur. J. Nucl. Med. 15:1989;265-268.
7. Ylitalo R., Mönkkönen J., Urtti A., Ylitalo P. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J. Lab. Clin. Med. 127:1996;200-206.
8. Ylitalo R., Kalliovalkama J., Ylitalo R., Pörsti I. Accumulation of bisphosphonates in human artery and their effect on human and rat arterial function in vitro. Pharmacol. Toxicol. 83:1998;125-131.
9. Hollander W., Paddock J., Nagraj S., Colombo M., Kirkpatrick B. Effects of anticalcifiying and antifibrotic drugs on preestablished atherosclerosis in the rabbit. Atherosclerosis. 33:1979;111-123.
10. Rosenblum I.Y., Flora L., Eisenstein R. The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis. Atherosclerosis. 22:1975;411-424.
11. Kramsch D.M., Chan C.T. The effect of agent interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ. Res. 42:1978;562-571.
12. Wagner W.D., Clarkson T.B., Foster J. Contrasting effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on the regression of two types of dietary-induced atherosclerosis. Atherosclerosis. 27:1977;419-435.
13. Price A.P., Samuel A.F., Williamson M.K. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler. Thromb. Vasc. Biol. 21:2001;817-824.
14. Ross R. The pathogenesis of atherosclerosis - a perspective for the 1990s. Nature. 362:1993;801-809.
15. Lusis A.J., Atherosclerosis Nature. 407:2000;233-241.
16. Felix R., Guenther H.L., Fleisch H. The subcellular distribution of [14]dichloromethylenebisphosphonate and [14]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif. Tissue Int. 36:1984;108-113.
17. Rogers M.J., Xiong X., Ji X., Mönkkönen J., Russell R.G., Williamson M.P. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. Pharm. Res. 14:1997;625-630.
18. Amin D., Cornell S.A., Gustafson S.K., Needle S.J., Ullrich J.W., Bilder G.E., Perrone M.H. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid. Res. 33:1992;1657-1663.
19. Luckmann S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13:1998;581-589.
20. Ziegler-Heitbrock L., Thiel E., Fütterer A., Herzog V., Wirtz A., Riethmüller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer. 41:1988;456-461.
21. Eiermann D.F., Johnson C.E., Haskill S.I. Human monocyte inflammatory mediator gene expression is selectively regulated by adherence substrates. J. Immunol. 142:1989;1970-1976.
22. Scheithe R., Heidenthal A.K., Danesch U., Mauthner E., Hapfelmeier G., Becker A., Pietsch A., Weber P.C., Hrboticky N. Acetylated LDL endocytosis by the human monocytic mono mac 6sr cells is not mediated by the macrophage type I and II scavenger receptor. Arterioscler. Thromb. Vasc. Biol. 17:1997;1024-1031.
23. Pietsch A., Erl W., Lorenz R.L. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem. Pharmacol. 52:1996;433-439.
24. Kielar D., Dietmaier W., Langmann T., Aslanidis C., Probst M., Naruszewicz M., Schmitz G. Rapid quantification of human ABCAI mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin. Chem. 47:2001;2089-2097.
25. Steuerwald N., Cohen J., Herrera R.J., Brenner C.A. Analysis of gene expression in single oocytes and embryos by real-time rapid cycle fluorescence monitored RT-PCR. Mol. Hum. Reprod. 5:1999;1034-1039.
26. Woo T.H.S., Patel B.K.C., Cinco M., Smythe L.-D., Symonds M.L., Norris M.A., Dohnt M.F. Real-time homogenous assay of rapid cycle polymerase chain reaction product for identification of Leptonerma illini. Anal. Biochem. 259:1998;112-117.
27. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assay. J. Mol. Endocrinol. 25:2000;169-193.
28. ABI Prism 7700 Sequence Detection System User Bulletin #2, Relative quantitation of gene expression, Applied Biosystems (1997).
29. Schulz T., Schiffl H., Scheithe R., Hrboticky N., Lorenz L. Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis. Am. J. Kidney Dis. 25:1995;564-571.
30. Hrbotitzky N., Draude G., Hapfelmeier G., Lorenz R., Weber P.C. Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized low density lipoproteins in human blood monocytes during the early stage of differentiation into macrophages. Arterioscler. Thromb. Vasc. Biol. 19:1999;1267-1275.
31. Basu S.K., Goldstein J.L., Anderson R.G., Brown M.S. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc. Natl. Acad. Sci. USA. 73:1976;3178-31821.
32. Osborne J.C. Delipidation of plasma lipoproteins. Methods Enzymol. 128:1986;213-222.
33. Markwell M.A.K., Haas S.M., Bieber L.L., Telbert M.E.A. Modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87:1987;206-210.
34. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V., Staels B. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of ABCA-1 pathway. Nat. Med. 7:2001;53-58.
35. Ravn P., Neugebauer G., Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone. 30:2002;320-324.
36. Neugebauer G., Hagena C., Sakalova A., Kaufmann B., Endele R. Pharmacokinetics of ibandronate, a highly potent antiresorptive drug on bone metabolism in patients with multiple myeloma. Eur. J. Clin. Pharmacol. 54:1998;18.
37. Mönkkönen J., Similä J., Rogers M.J. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci. 62:1998;95-102.
38. Tuominen O.M., Hollmen M., Jaakkola O., Mönkkönen J., Ylitalo R. Suppression of viability and acetyl-LDL metabolism in RAW 264 macrophage-like and smoth muscle cells by bisphosphonates in vitro. Methods Find. Exp. Clin. Pharmacol. 24:2002;487-492.
39. Danenberg H.D., Fishbein I., Gao J., Mönkkönen J., Reich R., Gati I., Moerman E., Golomb G. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation. 106:2002;599-605.
40. Ylitalo R., Syvälä H., Tuohimaa P., Ylitalo P. Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol. Toxicol. 90:2001;139-143.
41. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
42. Huh B.H.Y., Pearce S.F., Yesner L.M., Schindler J.L., Silverstein R.L. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood. 87:1996;2020-2028.
43. Ylitalo R., Mönkkönen J., Ylä-Herttuala S. Effects of liposome-encapsulated bisphosphonates on acetylated LDL metabolism, lipid accumulation and viability of phagozyting cells. Life Sci. 62:1998;413-422.
44. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:1997;20963-20966.
45. Goldstein J.L., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76:1979;333-337.
46. Scheithe R., Hrboticky N., Ziegler-Heitbrock H.W.L., Weber P.C. Receptor-specific uptake and degradation of acetylated, oxidized and native LDL in the human monocytic mono mac 6sr cell line. Biochem. Biophys. Res. Commun. 202:1994;334-339.
47. Terpstra V., van Amersfoort E.S., van Velzen A.G., Kuiper J., van Berkel T.J.C. Hepatic and extrahepatic scavenger receptors. Arterioscleros. Thromb. Vasc. Biol. 20:2000;1860-1872.
48. Repa J.J., Turley S.D., Lobaccaro J.M.A., Medina J., Li L., Lustig K., Shan B., Dietschy J.M., Mangelsdorf D.J. Regulation of absorption and ABC-1-mediated efflux of cholesterol by RXR heterodimers. Science. 289:2000;1524-1529.
49. Schwartz K., Lawn R.A., Wade D.P. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274:2000;794-802.
50. Costet P., Luo Y., Wang N., Tallm A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver x receptor/retinoid x receptor. J. Biol. Chem. 275:2000;28240-28245.
51. Forman B.M., Ruan B., Chen J., Schroepfer G.J., Evans R.M. The orphan nuclear receptor LXR is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. USA. 94:1997;10588-10593.
52. Gan X., Kaplan R., Menke J.G., MacNaul K., Chen Y., Sparrow C.P., Zhou G., Wright S.D., Cai T.Q. Dual mechanisms of ABCA-1 regulation by geranylgeranyl pyrophosphate. J. Biol. Chem. 276:2001;48702-48708.
53. Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G., Kaminski W.E., Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem. Biophys. Res. Commun. 257:1999;29-33.
54. Koshiyama H., Nakamura Y., Tanaka S., Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with typ 2 diabetes. J. Clin. Endocrinol. Metab. 85:2000;2793-2796.
55. Steinbuch M., D'Agostino R.B., Mandel J.S., Gabrielson E., McClung M.R., Stemhagen A., Hofman A. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Reg. Toxicol. Pharnacol. 35:2002;320-326.
56. Adami S., Braga V., Guidi G., Gatti D., Gerardi D., Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-densitiy lipoprotein cholesterol. J. Bone Miner. Res. 15:2000;599-604.
57. Montagnani A., Gonnelli S., Cepollaro C., Campagna M.S., Franci M.B., Pacini S., Gennai C. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone. 32:2003;15-19.
58. Ylitalo R. Bisphosphonates and atherosclerosis. Gen. Pharmacol. 35:2002;287-296.